Podcasts about Idiopathic pulmonary fibrosis

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a series of pivotal advancements and challenges shaping the industry landscape—ranging from scientific breakthroughs to regulatory maneuvers, all underscoring the sector's dynamic evolution. Novartis has made headlines with its investigational drug, Delpacibart Braxlosiran, which successfully met primary endpoints in a Phase 1/2 trial for treating Facioscapulohumeral Muscular Dystrophy (FSHD). This RNA therapy utilizes an antibody-oligonucleotide conjugate to target the DUX4 gene, a significant cause of FSHD. The promising results not only mark a potential therapeutic breakthrough for this debilitating neuromuscular disease but also highlight Novartis' commitment to innovative treatments in rare diseases. In parallel, Enliven Therapeutics has reported positive outcomes from a Phase 1 trial of ELVN-001 for patients with Chronic Myeloid Leukemia (CML), who are heavily pretreated. This small molecule tyrosine kinase inhibitor shows improved efficacy, offering hope for those who have exhausted existing treatment options. As ELVN-001 progresses into later-stage trials, it may significantly enhance therapeutic options and outcomes for CML patients. Regulatory activities remain at the forefront, exemplified by Amgen's engagement with the Duke Clinical Research Institute to defend Tavneos amid an FDA push for market withdrawal. This illustrates the intricate complexity of regulatory processes and the importance of evidence-based advocacy in preserving access to critical therapies. In another regulatory development, Guardant Health's Guardant360 CDx has received FDA approval as a companion diagnostic for Boehringer Ingelheim's Hernexeos targeting HER2-mutant non-small cell lung cancer. The approval emphasizes the growing significance of liquid biopsy technologies in personalized oncology care, offering precise and less invasive diagnostic solutions. In business development news, strategic collaborations are gaining momentum. Simcere Pharmaceutical has partnered with Stanford Medicine to develop first-in-class therapies for Idiopathic Pulmonary Fibrosis. Meanwhile, Ildong Pharmaceutical and Welt are joining forces to create AI-driven digital therapeutics. These alliances reflect an increasing trend towards integrating cutting-edge technology and cross-disciplinary expertise to accelerate drug discovery and development. Funding dynamics within the sector are evolving, as seen with Neion Bio's successful Series A fundraising of $23 million aimed at enhancing its biologics manufacturing platform. Similarly, Human Continuum secured $5.13 million to advance its exosome-based regenerative medicine platform. These investments underscore a strong focus on innovative platform technologies promising to transform therapeutic modalities and manufacturing processes. Not all news is positive, however; Jazz Pharmaceuticals and PharmaMar faced setbacks as their Phase 3 trial for Zepzelca (Lurbinectedin) failed to meet its overall survival endpoint in metastatic small cell lung cancer. This highlights the inherent challenges in oncology drug development and underscores the need for continuous innovation. Regulatory hurdles persist as well, evidenced by Camurus receiving a second complete response letter from the FDA regarding Oclaiz (Octreotide) due to manufacturing concerns. The industry is also navigating cybersecurity challenges, as seen with Novo Nordisk's recent data breach incident. This breach underscores vulnerabilities within biopharma companies concerning intellectual property and patient data protection. It serves as a stark reminder of the necessity for robust cybersecurity measures to safeguard sensitive information critical to clinical trials and corporate integrity. Meanwhile, strategic planning remains essential as Astellas confronts a looming $6 billion patent cliff with Xtandi, its prostate cancer drug. The company's five-year strategy focuses on cost savings while sustaining innovation and competitiveness amidst impending revenue declines. The biotechnology sector continues to thrive amidst these challenges, evidenced by record levels of initial public offerings (IPOs). Despite broader economic uncertainties, investor confidence remains robust, highlighting biotech's potential for groundbreaking advancements and lucrative returns. Finally, artificial intelligence is making significant strides across health agencies, with a reported 148% increase at the FDA by 2025 alone. This surge in AI integration highlights its transformative potential in regulatory processes and healthcare delivery—offering opportunities to enhance efficiency and decision-making within the sector. In summary, today's developments encapsulate the vibrant pharmaceutical and biotech industries characterized by scientific innovation, regulatory intricacies, strategic collaborations, and financial maneuvers. These advancements offer new hope for patients while navigating complex landscapes that demand continuous innovation and compliance—a balance that defines success in this ever-evolving sector.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of exciting advancements and strategic moves that are shaping the future of healthcare. Let's start with Pfizer's efforts in pneumococcal vaccination, a testament to the ongoing battle against Streptococcus pneumoniae. With their sights set on expanding protection and combating emerging health threats, Pfizer's initiatives reflect an industry-wide commitment to adapt to microbial challenges, potentially enhancing global public health outcomes. Their work underscores the crucial role vaccines play in preventing severe infections and maintaining public health. In other news, Parabilis Medicines is making strides by eyeing public markets to bolster its phase 3 tumor drug development. This move highlights the increasing reliance on public funding to advance late-stage clinical trials, which are essential for bringing new therapies to patients. Meanwhile, Lilly's acquisition of Engage for $202 million marks a significant expansion into non-viral DNA delivery systems. These systems could address traditional gene therapy challenges, promising more effective and safer genetic medicine options. Immunovant recently decided to discontinue its first-generation FcRn inhibitor after disappointing phase 3 results. This decision illustrates the unpredictable nature of drug development, where clinical evaluations often lead companies to reassess strategies based on trial outcomes. Such pivots are part and parcel of the rigorous scientific process that drives innovation forward. The integration of artificial intelligence in drug discovery is gaining momentum. Incyte's $80 million investment to expand its AI-driven partnership with Genesis is a clear indication of AI's growing importance in optimizing drug discovery. Similarly, Bristol Myers Squibb's collaboration with Anthropics Claude highlights a broader trend of leveraging AI across R&D processes to enhance efficiency and streamline operations. Additionally, Incyte's partnership with Edison Scientific to integrate Kosmos AI across R&D workflows exemplifies AI and machine learning's growing role in enhancing oncology drug discovery processes. Enter Oorja Bio, a newcomer focusing on idiopathic pulmonary fibrosis with a $30 million launch fund. Their novel approach to tackling this debilitating condition exemplifies the innovative spirit within smaller biotech firms aiming to address unmet medical needs. Oorja Bio's efforts are part of a larger movement in biotech where new entrants are making significant impacts by targeting specific diseases with fresh perspectives. On the regulatory front, Gilead has expanded its partnership with Korean manufacturer Yuhan through a $140 million deal for active pharmaceutical ingredients. This strategic move ensures robust supply chains amid evolving regulatory standards and market demands, underscoring the importance of global partnerships in maintaining drug availability and quality. Turning our attention to oncology, the American Society of Clinical Oncology (ASCO) 2026 conference is poised to be a significant event for industry professionals. The focus this year includes precision oncology and evolving trial designs, particularly for pancreatic cancer. The complexity of oncology studies demands tailored solutions for efficacy and regulatory compliance, pushing toward more adaptive and patient-centric trial designs. City of Hope's participation at ASCO emphasizes collaborative efforts in cancer research, combining cutting-edge science with comprehensive patient care to translate breakthroughs into tangible improvements in outcomes. Labcorp's involvement further underscores precision oncology's role through biomarker-driven trials and companion diagnostic development. The conversation at ASCO 2026 will also explore the future design of pancreatic cancer trials. By incorporating external controls and real-world data, researchers aim to streamline processes and expedite access to new therapies, acknowledging pancreatic cancer's unique challenges. In other significant advancements, UCB's Bimzelx showed superior efficacy over Skyrizi in treating psoriatic arthritis during a Phase 3 trial. As an IL-17A/IL-17F inhibitor, Bimzelx represents a promising biologic therapy option, potentially setting new standards in autoimmune treatment. Roche's voluntary license agreement with Medicines Patent Pool for Xofluza accessibility highlights efforts towards global health equity, ensuring essential medications reach low- and middle-income countries. Finally, financial movements such as Mentari Therapeutics' reverse merger raise substantial capital for neurological therapies, exemplifying ongoing investment confidence within the sector. These stories collectively illustrate an era marked by scientific innovation, strategic partnerships, and technological integration aimed at improving patient care and accelerating drug development pathways. As we continue to explore these advancements on Pharma Daily, stay tuned for more insights into how these developments shape our industry's future. That's all for today's episode of Pharma Daily. Thank you for tuning in as we navigate through these transformative times in pharmaceuticals and biotechnology.Support the show

Roger Seheult, MD of MedCram explains the history of idiopathic pulmonary fibrosis treatments, current medications, and a potential new treatment. See all Dr. Seheult's videos at: https://www.medcram.com/ (This video was recorded on April 9th, 2026) Roger Seheult, MD is the co-founder and lead professor at: www.medcram.com He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine. MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS: MedCram offers group discounts for students and medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested. MEDIA CONTACT:  Media Contact: customers@medcram.com Media contact info: https://www.medcram.com/pages/media-contact Video Produced by Kyle Allred Edited by Daphne Sprinkle of Sprinkle Media Consulting, LLC FOLLOW US ON SOCIAL MEDIA: Facebook:  www.facebook.com/MedCram Twitter/X: www.twitter.com/MedCramVideos Instagram: www.instagram.com/medcram DISCLAIMER: MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and strategic movements shaping the future of drug development and patient care.The pharmaceutical industry is seeing a flurry of mergers and acquisitions, reflecting a strategic push to enhance therapeutic portfolios. Biogen's $5.6 billion acquisition of Apellis Pharmaceuticals emphasizes its ambition to expand its immunology offerings and venture into kidney disease therapeutics. This move aligns with a broader industry trend where major players are investing heavily in acquisitions to bolster their pipelines and market positions. Similarly, Eli Lilly's $6.3 billion investment in Centessa Pharmaceuticals highlights its focus on diversifying its neuroscience portfolio, particularly in sleep disorder treatments. These strategic acquisitions underscore the high stakes and potential rewards associated with advancing treatments for neurological conditions.On the clinical front, United Therapeutics is making strides with its idiopathic pulmonary fibrosis program. A successful Phase 3 trial for Tyvaso positions it as a potential new standard in IPF treatment, paving the way for an FDA filing. This development underscores the company's ambition to secure blockbuster sales and expand its therapeutic footprint. However, AstraZeneca faced a setback when its Strensiq successor missed primary endpoints in a Phase 3 trial for treating rare metabolic diseases. This outcome illustrates the inherent risks in drug development, especially when expanding indications beyond existing pediatric uses.Regulatory scrutiny remains intense, with the FDA's Center for Biologics Evaluation and Research issuing untitled letters to several companies over promotional practices. This action highlights the importance of compliance in marketing biologics and emphasizes ethical promotional strategies that align with regulatory standards. Meanwhile, GSK's Exdensur secured regulatory approval in China for asthma treatment, marking a strategic expansion into a key geographical market.Economic pressures are also influencing the industry, as seen with BASF Pharma Solutions announcing price increases for excipients and some active pharmaceutical ingredients due to rising energy and raw material costs. Such moves reflect broader economic challenges impacting the pharmaceutical supply chain, emphasizing the ongoing need for cost-effective solutions in drug manufacturing.In obesity treatment innovation, Ambrosia Biosciences has raised $100 million to advance its oral small-molecule GLP-1 therapy into clinical trials. This funding round highlights growing investor interest in next-generation obesity treatments that move beyond traditional peptide-based approaches.Moreover, artificial intelligence is increasingly being harnessed to enhance clinical trial design efficiency. Bristol-Myers Squibb's collaboration with Faro exemplifies how AI technologies are streamlining clinical research processes to improve patient outcomes and accelerate drug development timelines.In other developments, Merck has presented compelling phase 3 results for its PCSK9 inhibitor, showcasing superiority over other oral non-statin therapies for cardiovascular diseases. This positions Merck strategically within the cardiovascular market by offering promising alternatives for patients intolerant to statins.Despite these advancements, some companies face challenges. Astellas Pharma discontinued an early-stage trial for Sjogren's syndrome treatment due to developmental hurdles, while Lipella Pharmaceuticals and Io Biotech filed for bankruptcy after struggling to advance their pipelines past regulatory obstacles.On the financial side, Blackstone's closure of a $6.3 billion life sciences fund underscores robust investor confidence in biotecSupport the show

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease that is often misdiagnosed, delaying treatment that can slow its course. Mridul Gupta, M.D., provides an overview of who is most affected, how to recognize and diagnose IPF, and what treatment approaches are available. Learn how clinicians and patients weigh the risks and benefits of treatment options (especially with older patients) and how more personalized therapies may be on the horizon. 

Luke Hedrick, Dave Furfaro, and recurrent RFJC guest Robert Wharton are joined again today by Nicole Ng to discuss the FIBRONEER-IPF trial investigating Nerandomilast in patients with IPF. This trial was published in NEJM in 2025 and looked at Neradomilast vs placebo for treating patients with IPF, on or off background anti-fibrotic therapy. This agents is now FDA approved for pulmonary fibrosis, and understanding the trial results is essential for any pulmonary physician treating patients with IPF or progressive pulmonary fibrosis. Article and Reference Today’s episode discusses the FIBRONEER-IPF trial published in NEJM in 2025. Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS; FIBRONEER-IPF Trial Investigators. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12;392(22):2193-2202. doi: 10.1056/NEJMoa2414108. Epub 2025 May 18. PMID: 40387033. https://www.nejm.org/doi/abs/10.1056/NEJMoa2414108 Meet Our Guests Luke Hedrick is an Associate Editor at Pulm PEEPs and runs the Rapid Fire Journal Club Series. He is a senior PCCM fellow at Emory, and will be starting as a pulmonary attending at Duke University next year. Robert Wharton is a recurring guest on Pulm PEEPs as a part of our Rapid Fire Journal Club Series. He completed his internal medicine residency at Mt. Sinai in New York City, and is currently a pulmonary and critical care fellow at Johns Hopkins. Dr. Nicole Ng is an Assistant Profess of Medicine at Mount Sinai Hospital, and is the Associate Director of the Interstitial Lung Disease Program for the Mount Sinai National Jewish Health Respiratory Institute. Infographic Key Learning Points Why this trial mattered IPF therapies remain limited: nintedanib and pirfenidone slow (but do not stop) decline and often cause GI side effects. Nerandomilast is a newer agent (a preferential PDE4B inhibitor) with antifibrotic + immunomodulatory effects. Phase 2 data (NEJM 2022) looked very promising (suggesting near-“halt” of FVC decline), so this phase 3 trial was a big test of that signal. Trial design essentials Industry-sponsored, randomized, double-blind, placebo-controlled, large multinational study (332 sites, 36 countries). Population: IPF diagnosed via guideline-aligned criteria with central imaging review and multidisciplinary diagnostic confirmation. Intervention: nerandomilast 18 mg BID, 9 mg BID, or placebo; stratified by background antifibrotic use. Primary endpoint: change in FVC at 52 weeks, analyzed with a mixed model for repeated measures. Key secondary endpoint: time to first acute exacerbation, respiratory hospitalization, or death (composite). Who was enrolled Typical IPF trial demographics: ~80% male, mean age ~70, many former smokers. Many were already on background therapy (~45% nintedanib, ~30–33% pirfenidone). Notable exclusions included significant liver disease, advanced CKD, recent major cardiovascular events, and psychiatric risk (suicidality/severe depression), reflecting class concerns seen with other PDE4 inhibitors. Efficacy: what the primary endpoint showed Nerandomilast produced a statistically significant but modest reduction in annual FVC decline vs placebo (roughly 60–70 mL difference). Importantly, it did not halt FVC decline the way the phase 2 data suggested; patients still progressed. Important nuance: interaction with pirfenidone Patients on pirfenidone had ~50% lower nerandomilast trough levels. Clinically: 9 mg BID looked ineffective with pirfenidone, so 18 mg BID is needed if used together. In those not on background therapy or on nintedanib, 9 mg and 18 mg looked similar—suggesting the apparent “dose-response” might be partly driven by the pirfenidone drug interaction Secondary and patient-centered outcomes were neutral No demonstrated benefit in the composite outcome (exacerbation/resp hospitalization/death) or its components. Quality of life measures were neutral and declined in all groups, emphasizing that slowing FVC alone may not translate into felt improvement without a disease-reversing therapy. The discussants noted this may reflect limited power/duration for these outcomes and mentioned signals from other datasets/pooling that might suggest mortality benefit—but in this specific trial, the key secondary endpoint was not positive. Safety and tolerability Diarrhea was the main adverse event: Higher overall with the 18 mg dose, and highest when combined with nintedanib (up to ~62%). Mostly mild/manageable; discontinuation due to diarrhea was relatively uncommon (but higher in those on nintedanib). Reassuringly, there was no signal for increased depression/suicidality/vasculitis despite psychiatric exclusions and theoretical class risk. How to interpret “modest FVC benefit” clinically The group framed nerandomilast as another tool that adds incremental slowing of progression. They emphasized that comparing absolute FVC differences across trials (ASCEND/INPULSIS vs this trial) is tricky because populations and “natural history” in placebo arms have changed over time (earlier diagnosis, improved supportive care, etc.). They highlighted channeling bias: patients already on antifibrotics may be sicker (longer disease duration, lower PFTs, more oxygen), complicating subgroup comparisons. Practical takeaways for real-world use All three antifibrotics are “fair game”; choice should be shared decision-making based on goals, tolerability, dosing preferences, and logistics. Reasons they favored nerandomilast in practice: No routine lab monitoring (major convenience advantage vs traditional antifibrotics). Generally better GI tolerability than nintedanib. BID dosing (vs pirfenidone TID). Approach to combination therapy: They generally favor add-on rather than immediate combination to reduce confusion about side effects—while acknowledging it may slow reaching “maximal therapy.” Dosing guidance emphasized: Start 18 mg BID for IPF, especially if combined with pirfenidone (since dose reduction may make it ineffective). 9 mg BID may be considered if dose reduction is needed and the patient is not on pirfenidone (e.g., monotherapy or with nintedanib).

Drs. Kaul and Adegunsoye discuss Veterans Affairs' innovative approach to understanding and treating pulmonary fibrosis among veterans by leveraging extensive electronic health records and data repositories. The work focuses on addressing healthcare disparities, exploring risk factors, and developing a hub-and-spoke telehealth model to provide specialized care to veterans in rural and underserved areas.

On today's Good Day Health Show - ON DEMAND…Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken discuss the biggest news stories in the medical world, starting with a focus on Tramadol and the risks associated with the opioid painkiller, used to treat moderate to severe pain in adults.Next up, the discussion shifts to Repatha, a prescription cholesterol medication, and the conflicting information coming out about cholesterol based on outdated research. Continuing on the drug discussions, the FDA has approved a new drug, Jascayd, used to treat adults with Idiopathic Pulmonary Fibrosis — a chronic progressive, and usually fatal, lung disease. While most may think of Botox as only a cosmetic injectable, it's also a medication. New research has found Botox to demonstrate statistically significant improvement in reducing the disability from the movement disorder associated with upper limb essential tremor compared to placebo.A continued focus on alcohol consumption and that even light alcohol consumption can still cause damage to the brain with risk levels of dementia rising with a link between alcohol consumption and negative cognitive outcome.Over the years, there has been research on symptoms of long-Covid, specifically brain fog — the inability to think as well as you did in the past — with advanced imaging showing widespread increase in the density of AMPA-receptors in the brains of long-Covid patients who suffer from brain fog.Rounding out the program, Doug and Dr. Ken address the government shut down and how it affects medical care. Currently, there isn't a great effect on the local basis, but the FDA is not currently approving new drugs or more new research grants during the shut down. Lastly, what it means when you have a good night's sleep and wake up feeling exhausted still, felling unrested.Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks

Evening Prayer (People with idiopathic pulmonary fibrosis and people who have been abandoned by their loved ones.) #pray #prayer #eveningprayer #christianprayer #jesus #god #holyspirit #idiopathicpulmonaryfibrosis #children #abandoned #love #peaceThank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for October 5-11, 2025: 1. FDA Approves Roflumilast (Zoryve) Cream 0.05% for Atopic Dermatitis in Children Aged 2-5 Years The FDA approved roflumilast cream 0.05% for mild to moderate atopic dermatitis in children aged 2–5 years, expanding Arcutis' roflumilast portfolio. 2. Nerandomilast Nets First New FDA Approval for Idiopathic Pulmonary Fibrosis in Over 10 Years Nerandomilast became the first newly approved therapy for idiopathic pulmonary fibrosis in over a decade, offering a well-tolerated option that slows lung function decline. 3. LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Long-term data confirmed mirikizumab provides durable clinical, endoscopic, and quality-of-life benefits for ulcerative colitis up to four years, even in patients who failed prior advanced therapy. 4. Bax24: Baxdrostat Achieves Primary Endpoint in Treatment-Resistant Hypertension Baxdrostat met its primary endpoint in a phase 3 trial for treatment-resistant hypertension, supporting its potential role as a new option for difficult-to-control blood pressure. 5. Topical Bimiralisib Shows 92% Clearance Rate for Patients with Actinic Keratosis  Phase 2 data showed topical bimiralisib achieved high lesion clearance with favorable tolerability in patients with actinic keratosis.

Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fibrosis.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

BUFFALO, NY — September 11, 2025 — A new #research paper was #published in Volume 17, Issue 8 of Aging-US on August 8, 2025, titled “AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging.” In this study, researchers Fedor Galkin, Shan Chen, Alex Aliper, Alex Zhavoronkov, and Feng Ren from Insilico Medicine used artificial intelligence (AI) to investigate the similarities between idiopathic pulmonary fibrosis (IPF), a severe lung disease, and the aging process. Their findings show that IPF is not simply accelerated aging, but a distinct biological condition shaped by age-related dysfunction. This insight may lead to a new approach in how scientists and clinicians treat this complex disease. IPF mainly affects individuals over the age of 60. It causes scarring of lung tissue, making it harder to breathe and often leading to respiratory failure. Current treatments can slow the disease but rarely stop or reverse its progression. The researchers used AI to identify shared biological features between aging and fibrosis, finding new potential targets for therapy. The team developed a “proteomic aging clock” based on protein data from more than 55,000 participants in the UK Biobank. This AI-driven tool accurately measured biological age and found that patients with severe COVID-19, who are at increased risk for lung fibrosis, also showed signs of accelerated aging. This suggests that fibrosis leaves a detectable biological trace, supporting the use of aging clocks in studying age-related diseases. “For aging clock training, we used the UK Biobank collection of 55319 proteomic Olink NPX profiles annotated with age and gender.” They also developed a custom AI model, ipf-P3GPT, to compare gene activity in aging lungs versus those with IPF. Although some genes were active in both, many showed opposite behavior. In fact, more than half of the shared genes had inverse effects. This means IPF does not just speed up aging but also disrupts the body's normal aging pathways. The study identified unique molecular signatures that distinguish IPF from normal aging. While both involve inflammation and tissue remodeling, IPF drives more damaging changes to lung structure and repair systems. This difference could guide the development of drugs that specifically target fibrosis without affecting normal aging. By combining AI with large-scale biological data, the study also introduces a powerful toolset for examining other age-related conditions such as liver and kidney fibrosis. These models may support personalized treatments and expand understanding of the relationships between aging and disease, opening new directions for therapy development. DOI - https://doi.org/10.18632/aging.206295 Corresponding author - Alex Zhavoronkov - alex@insilico.com Abstract video - https://www.youtube.com/watch?v=24lX2lHbt7o Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206295 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, IPF, generative AI, transformer, proteomics To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — September 4, 2025 — A new #research perspective was #published in Volume 17, Issue 8 of Aging (Aging-US) on August 16, 2025, titled “Age-related diseases as a testbed for anti-aging therapeutics: the case of idiopathic pulmonary fibrosis.” In this research perspective, Alex Zhavoronkov, Dominika Wilczok, Feng Ren, and Fedor Galkin, from Insilico Medicine, Buck Institute for Research on Aging, and Duke University, propose a new method to evaluate age-related diseases based on how closely they align with the biological processes of aging. Their analysis shows that idiopathic pulmonary fibrosis (IPF), a progressive lung condition, is one of the diseases most strongly associated with aging. This makes IPF a promising model for testing new anti-aging therapies with the potential to treat multiple age-related conditions. “This perspective explores how aging-related diseases (ARDs) can serve as experimental platforms for discovering new geroprotective interventions.” While many age-related diseases are used as models for aging research, not all accurately reflect the biology of aging. To address this, the authors developed a scoring system that measures how closely a disease is connected to the key hallmarks of aging, such as inflammation, genetic instability, and impaired cellular repair. Using this system, they evaluated 13 common age-related diseases and found that IPF had a particularly high overlap with aging biology. IPF is a chronic disease that causes scarring in the lungs and a rapid decline in lung function. In contrast to the gradual loss of function seen in normal aging, IPF progresses more than five times faster. The authors highlight that IPF shares nearly all of the biological features associated with aging. These similarities make IPF a strong candidate for studying aging and testing therapies that target its underlying causes. The authors also discuss different therapies currently being developed for IPF that are also designed to address aging itself. These include drugs that clear senescent cells, activate telomerase to maintain chromosome health, or repair damaged signaling between cells. Some of these treatments, such as senolytic combinations and AI-discovered compounds like rentosertib, are already showing early promise in preclinical or clinical trials. In addition, the authors point out that IPF's fast progression and clearly measurable outcomes offer an advantage for clinical testing. If a therapy proves effective in IPF, it may also be useful for other conditions that share similar aging-related mechanisms, including diabetes, arthritis, and heart disease. This approach could accelerate drug development and reduce costs by focusing on therapies that target shared biological pathways. Overall, this perspective supports a shift in pharmaceutical research toward treating aging as an underlying cause of many chronic diseases. By positioning IPF as a model for aging-related drug development, the authors propose a strategic pathway for testing and expanding anti-aging therapies across a wide range of health conditions. DOI - https://doi.org/10.18632/aging.206301 Corresponding author - Alex Zhavoronkov – alex@insilico.com Video short - https://www.youtube.com/watch?v=p5ur7itzvSI Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this episode, host Saranya Ravindran is joined by Toby Maher to explore the often-overlooked world of interstitial lung diseases. From clarifying common misconceptions to highlighting AI innovations and personalised treatments, the series dives deep into what clinicians need to know about these serious lung conditions. Whether you're new to interstitial lung diseases or experienced in respiratory care, this series offers timely insights and expert takeaways. Timestamps: 00:00: Introduction 00:41: Challenges in early diagnosis 03:22: ILD biomarkers 05:49: The overlap with autoimmune diseases 09:16: AI in ILD detection

In this episode, host Saranya Ravindran is joined by Toby Maher to explore the often-overlooked world of interstitial lung diseases. From clarifying common misconceptions to highlighting AI innovations and personalised treatments, the series dives deep into what clinicians need to know about these serious lung conditions. Whether you're new to interstitial lung diseases or experienced in respiratory care, this series offers timely insights and expert takeaways. Timestamps: 00:00: Introduction 00:40: Mainstays of treatment 04:42: Limitations of current antifibrotics 07:50: The future of ILD personalised care 13:40: Are we close to the reversal of fibrosis? 15:52: A message for clinicians

In this episode, host Saranya Ravindran is joined by Toby Maher to explore the often-overlooked world of interstitial lung diseases. From clarifying common misconceptions to highlighting AI innovations and personalised treatments, the series dives deep into what clinicians need to know about these serious lung conditions. Whether you're new to interstitial lung diseases or experienced in respiratory care, this series offers timely insights and expert takeaways.

In this episode, host Saranya Ravindran is joined by Toby Maher to explore the often-overlooked world of interstitial lung diseases. From clarifying common misconceptions to highlighting AI innovations and personalised treatments, the series dives deep into what clinicians need to know about these serious lung conditions. Whether you're new to interstitial lung diseases or experienced in respiratory care, this series offers timely insights and expert takeaways. Timestamps: 00:00: Introduction 02:00: ILD landscape: UK versus USA 04:33: What falls under the ILD umbrella? 06:38: Idiopathic pulmonary fibrosis 07:58: Understanding different patient profiles 09:28: Early clinical signs of ILD

MaryLuz Fuentes, MD, a former clinician and double-lung transplant survivor will typically say this to other IPF patients: "We patients may be short of breath, but not short of hope." On this episode with host Patti Tripathi, Dr. Fuentes talks about what led up to her double-lung transplant three years ago and what's in store for her at the ATS 2025 International Conference in May. 

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Our episode today is diving into a broader initiative to discuss the management of interstitial lung disease. In this episode we will be talking about the treatment of Idiopathic Pulmonary Fibrosis through the lens of a journal club discussion of … Continue reading →

Today's guest is Terri Pilawa. Terri started feeling ill in 2008 and was finally diagnosed correctly after 4 years of not knowing what was wrong in 2012 with Idiopathic Pulmonary Fibrosis. She was told she needed a lung transplant. In 2015, she had a successful double lung transplant. As a part of her journey she became involved with the One Breath Foundation and is now the CEO. Let's hear about both her IPF journey and her involvement in the One Breath Foundation.

Idiopathic Pulmonary Fibrosis (IPF) is a devastating lung disease affecting millions worldwide, with a grim prognosis of only three to five years post-diagnosis. In this episode, leading lung disease expert Victor Thannickal, MD, delves into the symptoms, progression, and impacts of IPF. He also sheds light on promising new drug therapies emerging from his lab, offering hope in the fight against this relentless disease. Host Elaine Hamm, PhD, skillfully navigates the complex landscape of IPF, making this a must-listen for anyone interested in cutting-edge biotech developments. If you enjoyed the episode, please consider liking, sharing, and subscribing to BIO from the BAYOU. Your support helps us continue delivering high-quality content to listeners passionate about the biotech industry.

Host: Jonathan Chung, MD Host: Seth Kligerman, MD Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach.

CME credits: 1.00 Valid until: 07-11-2024 Claim your CME credit at https://reachmd.com/programs/clinicians-roundtable/idiopathic-pulmonary-fibrosis-the-role-of-radiology-in-accurate-and-timely-diagnosis/18077/ Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach. =

Dr. Sunad Rangarajan chats with Dr. Corrine Kliment about her article, "Loss of ANT1 Increases Fibrosis and Epithelial Cell Senescence in Idiopathic Pulmonary Fibrosis." 

Join us on a remarkable journey with Alastair Henry, the adventurous boomer and double lung transplant survivor who turned his life around post-retirement. From the corporate boardrooms to the remote Canadian North, to volunteering across the globe, Alastair's story is a testament to living life to the fullest. Discover how he embraced indigenous wisdom, tackled idiopathic pulmonary fibrosis, and found joy in simplicity on this inspiring episode of the Living the Dream podcast with Curveball.

Dr. Mohleen Kang chats with Dr. Aparna Swaminathan and Dr. Timothy Dempsey about their articles, "External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources” and “The Added Power of Synthetic Control Groups: Challenging Conventional Wisdom and Trial Design in Idiopathic Pulmonary Fibrosis Research.” 

The publication of this podcast was funded by CSL Behring. The views and opinions expressed are exclusively those of the speakers. In this section, the panel considers the diagnostic tools and approaches available for healthcare professionals to use for suspected idiopathic pulmonary fibrosis (IPF). The discussion is directed towards the expertise of Prof. Luca Richeldi, who emphasises the importance of knowledge, education, and medical examination approaches for addressing the unmet medical needs associated with the awareness of, and diagnostic delays of IPF.

The publication of this podcast was funded by CSL Behring. The views and opinions expressed are exclusively those of the speakers.   In this section, the panel considers the expert insights of Prof. Wijsenbeek, concerning the challenges of predicting the disease course and prognosis of patients with idiopathic pulmonary fibrosis (IPF). The conversation reflects on current knowledge, real-world practices, treatment options, and tools available to healthcare professionals.

Idiopathic Pulmonary Fibrosis, or IPF, is a progressive lung disease with genetic and environmental causes, affecting 5 million people globally. Although pollutants have long been linked to a range of lung diseases,  no conclusive evidence regarding their link to IPF has been sought thus far. The research of Dr. Eun Joo Kim, a post-doctorate researcher at The University of Colorado Anschutz Medical Campus, defines the role of cilia in lung repair following injury, and details how cilia related genes may be responsible for the severity of symptoms.Read the original article: https://doi.org/10.1165/rcmb.2021-0554OC

Ben Verlander welcomes New York Yankees legend Bernie Williams back to the show. They discuss the current state of the New York Yankees, what it meant to have his number retired and what advice he would give Shohei Ohtani during free agency. They also talk about his favorite Derek Jeter story, what he sees in Yankees' Jasson Dominguez and his thoughts on New York Mets new manager Carlos Mendoza. Bernie also talks about National Caregivers Month, his father's battle with Idiopathic Pulmonary Fibrosis (or IPF) and his work with Boehringer Ingleheim & the Tune In To Lung Health Program. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast, Drs Jeffrey Swigris and Toby Maher discuss the future of idiopathic pulmonary fibrosis. Find out where we're headed regarding diagnostic and treatment innovations on the near horizon. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982426). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Idiopathic Pulmonary Fibrosis: Present Understanding and Future Options https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584113/ Predicting Prognosis in Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/21319590/ Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/35569036/ Inhaled Treprostinil and Forced Vital Capacity in Patients With Interstitial Lung Disease and Associated Pulmonary Hypertension: A Post-hoc Analysis of the INCREASE Study https://pubmed.ncbi.nlm.nih.gov/34214475/ Pulmonary Fibrosis Foundation https://www.pulmonaryfibrosis.org/ Predictors of Progression in Systemic Sclerosis Patients With Interstitial Lung Disease https://pubmed.ncbi.nlm.nih.gov/32079645/

In this special episode Liz tells us about her experience of living with RA-ILD, which is short for rheumatoid arthritis-associated interstitial lung disease. We explore the profound impact of this life-changing diagnosis on Liz and her loved ones as well as the need for increased awareness of the condition. Throughout Liz provides advice and strategies for maintaining a positive outlook despite the challenges RA-ILD presents.

This episode covers interstitial lung disease, including idiopathic pulmonary fibrosis.Written notes can be found at https://zerotofinals.com/medicine/respiratory/interstitiallungdisease/ or in the respiratory section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.

Dr Jeffrey J. Swigris and Professor Anne Holland discuss the finer points of oxygen therapy for patients with idiopathic pulmonary fibrosis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982425). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Home Oxygen Therapy for Adults With Chronic Lung Disease: An Official ATS Clinical Practice Guideline Implementation Tools https://www.thoracic.org/statements/guideline-implementation-tools/home-oxygen-therapy-for-adults.php The King's Brief Interstitial Lung Disease (KBILD) Questionnaire: An Updated Minimal Clinically Important Difference https://bmjopenrespres.bmj.com/content/6/1/e000363 Ambulatory Oxygen for Treatment of Exertional Hypoxaemia in Pulmonary Fibrosis (PFOX Trial): A Randomised Controlled Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737108/

In this episode, we explore how innovating today could have a positive impact on those diagnosed with pulmonary fibrosis. We are joined by extraordinary guests, including researchers, healthcare providers, innovators, and a patient impacted by this rare disease. Keeping patients' lived experiences front and center can help lead to new ideas and progress, all while inspiring us to remain hopeful for the future.

Editor's Summary by Anne Rentoumis Cappola, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the May 9, 2023, issue. Related Content: Audio Highlights

KSQD 5-06-2023: Advances in anti-aging drugs; A survey of many brain-computer interface devices available and being developed

Drs Jeffrey Swigris and Marlies Wijsenbeek discuss how to best manage care for patients with idiopathic pulmonary fibrosis using remote monitoring to address quality-of-life concerns. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982423). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Remote Monitoring in Idiopathic Pulmonary Fibrosis: Home Is Where the Bluetooth-Enabled Spirometer Is https://www.atsjournals.org/doi/full/10.1164/rccm.202005-1532ED Challenges in Pulmonary Fibrosis – 1: Use of High Resolution CT Scanning of the Lung for the Evaluation of Patients With Idiopathic Interstitial Pneumonias https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117220/ Spirometry: Step by Step https://breathe.ersjournals.com/content/8/3/232

Drs Jeffrey Swigris and Ayodeji Adegunsoye discuss fibrosing interstitial lung disease and treatment challenges for individuals with idiopathic pulmonary fibrosis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982422). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Idiopathic Pulmonary Fibrosis (An Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline https://pubmed.ncbi.nlm.nih.gov/35486072/ Health-Related Quality of Life and Symptoms in Patients With IPF Treated With Nintedanib: Analyses of Patient-Reported Outcomes From the INPULSIS® Trials https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990488/ Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Clinical Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089322/

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease that leads to progressive lung scaring and eventual respiratory failure; it most often affects the elderly. The American Thoracic Society and other international bodies updated clinical practice guidelines for this disease in 2022. Tracy Luckhardt, MD, a pulmonologist, summarizes the most important changes to diagnosis, pharmacological treatments, and non-pharmacological treatments. Learn more about the advantages of an interdisciplinary team in managing symptoms and comorbidities of IPF, including determining when a patient is a good candidate for clinical trials or a lung transplant.

Idiopathic pulmonary fibrosis (IPF) is one of the common forms of interstitial lung disease (those that affect the tissues between airways); it results in scarring and fibroblasts. Early diagnosis is critical to the management of this dangerous condition. Carla Copeland, MD, explains the challenge of diagnosing IPF due to its generic symptoms, which usually indicate more common breathing issues. She discusses recent innovations in how CT scans are categorized to better diagnose IPF and to help recommend patients for biopsies. Learn why Dr. Copeland works with a multidisciplinary discussion team (MDT) to diagnose this condition accurately and to begin treatment as soon as possible.

2.12 Idiopathic Pulmonary Fibrosis   Pulmonary system review for the USMLE Step 1 exam.

Idiopathic Pulmonary Fibrosis with Dr Horne by Dr. Laura Caputo

Moderators Aravind M Menon, MD, MPH, and Alice Gallo de Moraes, MD, and journal CHEST® author Sahajal Dhooria, MD, DM, discuss the article, "MUC5B Promoter Polymorphism and Survival in Indian Patients With Idiopathic Pulmonary Fibrosis," which was published in the October issue. DOI: https://doi.org/10.1016/j.chest.2022.04.001

How does dapagliflozin affect kidney outcomes in patients hospitalized with COVID-19? Find out about this and more in today's PV Roundup podcast.